EW Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.54B

+11.31%

0.619

+4.95%

1.57B

+10.91%

0.680

+6.21%

1.67B

+8.95%

0.725

+8.22%

Estimates Revision

The market is revising Upward the revenue expectations for Edwards Lifesciences Corporation (EW) for FY2025, with the revenue forecasts being adjusted by 1% over the past three months. During the same period, the stock price has changed by 13.59%.

Revenue Estimates for FY2025

Revise Upward

+1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.03%

In Past 3 Month

Stock Price

Go Up

+13.59%

In Past 3 Month

24 Analyst Rating

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

10 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

83.00

Averages

92.95

High

104.00

Current: 0.000

Low

83.00

Averages

92.95

High

104.00

Goldman Sachs

David Roman

Buy

maintain

$104 -> $108

2026-01-09

New

Reason

Goldman Sachs

David Roman

Price Target

$104 -> $108

2026-01-09

New

maintain

Buy

Reason

Goldman Sachs analyst David Roman raised the firm's price target on Edwards Lifesciences to $108 from $104 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

TD Cowen

Hold

Buy

upgrade

$90 -> $97

2026-01-09

New

Reason

TD Cowen

Price Target

$90 -> $97

2026-01-09

New

upgrade

Hold

Buy

Reason

TD Cowen upgraded Edwards Lifesciences to Buy from Hold with a price target of $97, up from $90. The firm thinks the company has entered a renewed growth cycle, driven by TAVR indication expansion, reinforced Sapien durability from the seven-year PARTNER 3 results, and accelerating momentum with Evoque. TD sees a path to sustained double-digit organic growth for Edwards.

Evercore ISI

Outperform

maintain

$92 -> $94

2026-01-05

New

Reason

Evercore ISI

Price Target

$92 -> $94

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Edwards Lifesciences to $94 from $92 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

JPMorgan

Neutral -> Overweight

upgrade

$90 -> $100

2025-12-18

Reason

JPMorgan

Price Target

$90 -> $100

2025-12-18

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Edwards Lifesciences to Overweight from Neutral with a price target of $100, up from $90. The firm sees good visibility into share outperformance in 2026 for Edwards. The company's "robust" innovation pipeline should support sustainable premium growth over the longer term, the analyst tells investors in a research note. JPMorgan believes the company provided "conservative" 2026 guidance that is beatable as transcatheter aortic valve replacement continues to accelerate.

Canaccord

William Plovanic

Hold

downgrade

$89 -> $87

2025-12-17

Reason

Canaccord

William Plovanic

Price Target

$89 -> $87

2025-12-17

downgrade

Hold

Reason

Canaccord analyst William Plovanic lowered the firm's price target on Edwards Lifesciences to $87 from $89 and keeps a Hold rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

Baird

David Rescott

Neutral

downgrade

$88 -> $87

2025-12-16

Reason

Baird

David Rescott

Price Target

$88 -> $87

2025-12-16

downgrade

Neutral

Reason

Baird analyst David Rescott lowered the firm's price target on Edwards Lifesciences to $87 from $88 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Valuation Metrics

The current forward P/E ratio for Edwards Lifesciences Corp (EW.N) is 30.98, compared to its 5-year average forward P/E of 34.64. For a more detailed relative valuation and DCF analysis to assess Edwards Lifesciences Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

34.64

Current PE

30.98

Overvalued PE

41.57

Undervalued PE

27.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

27.15

Current EV/EBITDA

23.65

Overvalued EV/EBITDA

32.77

Undervalued EV/EBITDA

21.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.10

Current PS

7.65

Overvalued PS

11.23

Undervalued PS

6.97

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased368.75%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EW News & Events

Events Timeline

No data

News

7.5

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

7.0

2025-12-24PRnewswire

Halper Sadeh Investigates Edwards Lifesciences for Potential Fiduciary Breaches

9.0

2025-12-23SeekingAlpha

Edwards Lifesciences receives FDA approval for SAPIEN M3 TMVR system

People Also Watch

Frequently Asked Questions

What is Edwards Lifesciences Corp (EW) stock price today?

The current price of EW is 85.405 USD — it has increased 0.98 % in the last trading day.

What is Edwards Lifesciences Corp (EW)'s business?

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

What is the price predicton of EW Stock?

What is Edwards Lifesciences Corp (EW)'s revenue for the last quarter?

Edwards Lifesciences Corp revenue for the last quarter amounts to 1.55B USD, increased 14.67 % YoY.

What is Edwards Lifesciences Corp (EW)'s earnings per share (EPS) for the last quarter?

Edwards Lifesciences Corp. EPS for the last quarter amounts to 0.50 USD, decreased -90.25 % YoY.

What changes have occurred in the market's expectations for Edwards Lifesciences Corp (EW)'s fundamentals?

How many employees does Edwards Lifesciences Corp (EW). have?

Edwards Lifesciences Corp (EW) has 15800 emplpoyees as of January 09 2026.

What is Edwards Lifesciences Corp (EW) market cap?

Today EW has the market capitalization of 49.08B USD.